Biodexa Pharmaceuticals announces outcome of a Type C meeting with FDA on eRapa
Biodexa Pharmaceuticals (BDRX) announced the results of its Type C meeting with the U.S. Food and Drug Administration, FDA, regarding the ...
The Manila Times4d
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Nasdaq3d
Biodexa Pharma To Initiate Registrational Phase 3 Study Of ERapa In FAP In Next Quarter
(RTTNews) - Biodexa Pharmaceuticals PLC (BDRX), a clinical stage biopharmaceutical company, Monday announced results of its Type C meeting with the U.S. Food and Drug Administration (FDA ...
Yahoo Finance4d
Biodexa Pharmaceuticals Plc (BDRX)
March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U ...
Nasdaq4d
Biodexa Pharmaceuticals PLC Achieves Key Milestone with FDA Following Type C Meeting for Phase 3 eRapa Study in Familial Adenomatous Polyposis
Biodexa Pharmaceuticals announced a successful Type C meeting with the FDA, which has cleared the way to finalize the Phase 3 protocol for its drug eRapa in treating familial adenomatous polyposis ...
Wane17d
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...
Morningstar8d
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...
MT Newswires on MSN1d
European Equities Traded in the US as American Depositary Receipts Lower Wednesday
European equities traded in the US as American depositary receipts were lower late Wednesday morning, declining 0.21% to 1,391.26 on the S&P Europe Select ADR Index. From continental Europe, the ...
Morningstar4d
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...
Yahoo Finance23d
Biodexa Pharmaceuticals Plc (BDRX)
February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well ...